The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Arrowhead Pharmaceuticals Inc shares valued at $761,709 were purchased by Myszkowski Kenneth Allen on Jul 10 ’25. At $19.04 per share, Myszkowski Kenneth Allen acquired 40,000 shares.
Also, Anzalone Christopher Richard sold 50,800 shares, netting a total of over 583,692 in proceeds. Following the sale of shares at $11.49 each, the insider now holds 3,921,255 shares.
Before that, Anzalone Christopher Richard had sold 50,000 shares from its account. In a trade valued at $543,500, the Chief Executive Officer traded Arrowhead Pharmaceuticals Inc shares for $10.87 each. Upon closing the transaction, the insider’s holdings decreased to 50,000 shares, worth approximately $74.87 million.
As published in their initiating research note from Goldman on June 05, 2024, Arrowhead Pharmaceuticals Inc [ARWR] has been a Neutral and the price target has been revised to $31. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of September 19, 2023, Citigroup has initiated its “Neutral” rating for ARWR. Earlier on July 21, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ARWR stock.
Analyzing ARWR Stock Performance
On last trading session,, Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] rose 3.01% to $18.85. The stock’s lowest price that day was $18.155, but it reached a high of $19.045 in the same session. During the last five days, there has been a drop of approximately -0.05%. Over the course of the year, Arrowhead Pharmaceuticals Inc shares have dropped approximately -34.68%.
Support And Resistance Levels for Arrowhead Pharmaceuticals Inc (ARWR)
RSI (Relative Strength Index) is 65.12 on the 14-day chart, showing neutral technical sentiment.
Is Arrowhead Pharmaceuticals Inc subject to short interest?
Stocks of Arrowhead Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.56 million shares to 12.68 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 13.24 million shares. A decline of -4.44% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.95 of the overall float, the days-to-cover ratio (short ratio) decline to 6.95.
Which companies own the most shares of Arrowhead Pharmaceuticals Inc (ARWR)?
In terms of Arrowhead Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 30.48 in the next 12 months, up nearly 66.58% from the previous closing price of $18.3. Analysts anticipate Arrowhead Pharmaceuticals Inc stock to reach 52 by 2025, with the lowest price target being 24. In spite of this, 9 analysts ranked Arrowhead Pharmaceuticals Inc stock as Buy at the end of 2025. On May 12, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and downgraded coverage with a $40.
